- Home
- PHUN vs JSPR Comparison
PHUN vs JSPR Comparison
Compare PHUN & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHUN | JSPR |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | United States | United States |
| Employees | 26 | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.1M | 26.3M |
| IPO Year | 2016 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PHUN | JSPR |
|---|---|---|
| Price | $2.01 | $0.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | $7.25 | ★ $15.50 |
| AVG Volume (30 Days) | 96.4K | ★ 322.1K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.36 | 19.22 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,883,000.00 | N/A |
| Revenue This Year | $89.86 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.57 | N/A |
| 52 Week Low | $1.56 | $0.32 |
| 52 Week High | $3.13 | $2.69 |
Technical Indicators
Market Signals| Indicator | PHUN | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 41.67 | 45.39 |
| Support Level | $1.95 | $0.64 |
| Resistance Level | $2.11 | $1.01 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 31.25 | 44.56 |
Price Performance
Historical ComparisonAbout PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services. Development services for customers who wish to have a customized application experience; and In-app advertising services for mobile audience building, user acquisition, application discovery, audience engagement and monetization.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.